Contemporary medical science has traced thousands of clinical conditions to a genetic cause. Cancer, a life-threatening disease, also has genetic origins, and is considered among the leading causes of death across the globe. In fact, the World Health Organization (WHO) has reported that close to 10 million cancer related deaths annually, across the world. Moreover, experts believe that there are over 7,000 different types of rare diseases (including some rare forms of cancer), most of which originate as a consequence of genetic anomalies. The majority of the aforementioned conditions are still considered incurable. As a result, these disease areas are characterized by a significant unmet need for curative interventions; and therefore, considered among the most lucrative opportunity areas for biopharmaceutical developers. For example, ZOLGENSMA®, a blockbuster product developed by Novartis, and indicated for the treatment of spinal muscular atrophy, generated net revenues of approximately USD 1.35 billion in 2021 alone. The first gene therapy trial was conducted in 1990, and it took almost three decades for the first of such interventions to enter the market. Given recent developments in genetic manipulation, cell biology and molecular targeting, a number of highly specific interventions have been developed against prominent types of cancers and certain rare genetic conditions. Currently, there are over 20 cell and gene therapies approved for use in the United States alone.
During the COVID-19 pandemic, the pace of R&D in this field slowed down - a consequence of complex manufacturing protocols, extensive logistical considerations and supply chain-related concerns. However, the field still witnessed a considerable inflow of capital, with over USD 21 billion invested into various companies since the start of the pandemic. With over 1,200 product candidates in various stages of development, experts suggest that, by 2025, the US FDA may start approving around 10 to 20 cell and gene therapy products, on an annual basis. It is likely that, over the next two decades, gene therapies facilitate the evolution of medical practice from a treatment-based paradigm to a prevention-focused approach. Despite the fact that niche startups are spearheading the innovation in this domain, several big pharma players are also actively acquiring capabilities related to upcoming advanced therapy medical products (ATMPs). Prominent players in the field, such as Juno Therapeutics, AveXis, and Kite Pharma, have been acquired as a consequence of the rapid expertise building efforts of more established pharma companies. Moreover, gene therapy-focused businesses that have gone public, have experienced considerable growth in share value as their respective products / product candidate progressed through the various stages of development. Taking into consideration both the historical and contemporary scenario, the cell and gene therapies market continues to present lucrative investment opportunities for both short- and long-term investors.
The “Investor Series: Opportunities in the Cell and Gene Therapy Market” report provides detailed information on the cell and gene therapy industry, covering both core and peripheral products, and affiliated services. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data.
Spreadsheet I includes details on the key innovator companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, inputs for a detailed company competitiveness analysis and a shortlist of industry stakeholders that were deemed to be likely targets of mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated within.
Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in cell and gene therapies (since 2011).
Spreadsheet III showcases our proprietary company valuation analysis, wherein we have developed the means to extrapolate publicly information (related to valuation of specific companies) to develop informed estimates of the likely value of a company.
Spreadsheet IV is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the key innovators dataset.
Spreadsheet V offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.
Spreadsheet VI is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with cell and gene therapies.
Spreadsheet VII includes publicly available information on the investments made by select investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on likely returns on investment received by the mentioned investors.
Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for cell and gene therapies. It goes on to discuss some of the key benefits of these medical products and their advantages over other available drugs / therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.
Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study.
Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.
Chapter 5 describes the current need for cell and gene therapies, and highlights key facts about the origin and development of such ATMPs. It features information on current areas of innovation, along with the opinions of experts, describing the various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain, along with examples of ventures that have either succeeded or failed in the market. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts). It concludes with information on the different conferences that have been conducted in this domain in the recent past, and those that are planned for the near future.
Chapter 6 focuses on some of the key innovators (companies established on or after 2005) and features detailed analysis of the aforementioned companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.
Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and type of product. Based on the aforementioned insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies.
Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely, treatment-related value offered, value to patients and technology related value, we developed an empirical framework to quantify the value proposition of a business.
Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developed of diverse cell and gene therapies captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criteria, which was informed via our company health indexing and valuation exercise.
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report.
Chapter 11 features a proprietary basis for estimating the relative valuation of private companies, among the key innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall cell and gene therapy market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of six of the publicly listed companies within the key innovators dataset.
Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.
Chapter 14 features is an insightful market forecast analysis, highlighting the estimated current and future sizes of overall cell and gene therapy market till the year 2035. The opportunity has been segregated on the basis of [A] key market segments (namely stem cell therapies, gene therapies and T-cell therapies) ) [B] therapeutic areas (namely oncological disorders, genetic disorders, metabolic disorders and others) [C] routes of administration (intravenous and others) and [D] geography (North America, Europe, Asia Pacific and the rest of the world) .
Chapter 15 includes case studies of instances where investors have exited various cell and gene therapy-related ventures, offering insights on returns on investment made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time.
Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.
Chapter 17 provides a pictorial summary of the overall project.
Chapter 18 is a set of appendices.
During the COVID-19 pandemic, the pace of R&D in this field slowed down - a consequence of complex manufacturing protocols, extensive logistical considerations and supply chain-related concerns. However, the field still witnessed a considerable inflow of capital, with over USD 21 billion invested into various companies since the start of the pandemic. With over 1,200 product candidates in various stages of development, experts suggest that, by 2025, the US FDA may start approving around 10 to 20 cell and gene therapy products, on an annual basis. It is likely that, over the next two decades, gene therapies facilitate the evolution of medical practice from a treatment-based paradigm to a prevention-focused approach. Despite the fact that niche startups are spearheading the innovation in this domain, several big pharma players are also actively acquiring capabilities related to upcoming advanced therapy medical products (ATMPs). Prominent players in the field, such as Juno Therapeutics, AveXis, and Kite Pharma, have been acquired as a consequence of the rapid expertise building efforts of more established pharma companies. Moreover, gene therapy-focused businesses that have gone public, have experienced considerable growth in share value as their respective products / product candidate progressed through the various stages of development. Taking into consideration both the historical and contemporary scenario, the cell and gene therapies market continues to present lucrative investment opportunities for both short- and long-term investors.
Scope of the Report
The “Investor Series: Opportunities in the Cell and Gene Therapy Market” report provides detailed information on the cell and gene therapy industry, covering both core and peripheral products, and affiliated services. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data.
The report features the following details:
- A qualitative and quantitative (wherever information was available) perspective on the current need for cell and gene therapies. It also provides information on some of the important applications of cell and gene therapies, the benefits of using such therapies over conventional treatment options, the various challenges faced in the development / production of these ATMPs, and the opinions of representatives from key stakeholder companies involved in this domain. It also includes details of some exemplary ventures that have either succeeded or failed in this market, and highlights the various events, related to this field of research, which have already taken place, or yet to take place, since 2020.
- A detailed analysis of cell and gene therapy focused companies that were established on or after 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, headquarters, company size, and type of venture.
- A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, which was informed via secondary research.
- An assessment of the various products and affiliated services, offered by the companies mentioned above, featuring analysis based on number and type of product, and an informed perspective on the value of the aforementioned offerings based on multiple relevant aspects, namely, therapy-related value, value to patients, developer value, and others.
- A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in the development of cell and gene therapies / product candidates, captured in this report. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analyses.
- A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. Further, it features a list of the leading investors in cell and gene therapy market, based on their participation in financing activity in this industry segment.
- A proprietary analysis defining a basis for estimating the relative valuation of the private companies among the key innovators discussed in this report. The value statements generated under this analytical framework, were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were then extrapolated using the appropriate mathematical models to generate the likely valuation estimates for all the companies in the dataset.
- An elaborate review of the overall cell and gene therapy market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the key innovators dataset.
- A business risk analysis, focused on some of the major categories of risk that are usually discussed in the industry – namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks.
- Case studies of instances where investors have exited various cell and gene therapy-related ventures, offering insights on returns on investment made (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the cell and gene therapy market.
- A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers.
- One of the key objectives of the report was to evaluate the current opportunity and the future potential of cell and gene therapies over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035. The opportunity has been segregated on the basis of [A] key market segments (namely stem cell therapies, gene therapies and T-cell therapies) [B] therapeutic areas (namely oncological disorders, genetic disorders, metabolic disorders and others) [C] routes of administration (intravenous and others) and [D] geography (North America, Europe, Asia Pacific and the rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
EXCEL DELIVERABLE
Spreadsheet I includes details on the key innovator companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, inputs for a detailed company competitiveness analysis and a shortlist of industry stakeholders that were deemed to be likely targets of mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated within.
Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in cell and gene therapies (since 2011).
Spreadsheet III showcases our proprietary company valuation analysis, wherein we have developed the means to extrapolate publicly information (related to valuation of specific companies) to develop informed estimates of the likely value of a company.
Spreadsheet IV is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the key innovators dataset.
Spreadsheet V offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.
Spreadsheet VI is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with cell and gene therapies.
Spreadsheet VII includes publicly available information on the investments made by select investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on likely returns on investment received by the mentioned investors.
POWERPOINT DELIVERABLE
Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for cell and gene therapies. It goes on to discuss some of the key benefits of these medical products and their advantages over other available drugs / therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.
Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study.
Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.
Section I: Need for Cell and Gene Therapies & Key Innovators Landscape
Chapter 5 describes the current need for cell and gene therapies, and highlights key facts about the origin and development of such ATMPs. It features information on current areas of innovation, along with the opinions of experts, describing the various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain, along with examples of ventures that have either succeeded or failed in the market. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts). It concludes with information on the different conferences that have been conducted in this domain in the recent past, and those that are planned for the near future.
Chapter 6 focuses on some of the key innovators (companies established on or after 2005) and features detailed analysis of the aforementioned companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.
Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and type of product. Based on the aforementioned insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies.
Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely, treatment-related value offered, value to patients and technology related value, we developed an empirical framework to quantify the value proposition of a business.
Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developed of diverse cell and gene therapies captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criteria, which was informed via our company health indexing and valuation exercise.
Section II Analysis of Investments & Company Valuation
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report.
Chapter 11 features a proprietary basis for estimating the relative valuation of private companies, among the key innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.
Section III Financial Analysis & Assessment of Business Risks
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall cell and gene therapy market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of six of the publicly listed companies within the key innovators dataset.
Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.
Section IV Market Forecast & Opportunity Analysis
Chapter 14 features is an insightful market forecast analysis, highlighting the estimated current and future sizes of overall cell and gene therapy market till the year 2035. The opportunity has been segregated on the basis of [A] key market segments (namely stem cell therapies, gene therapies and T-cell therapies) ) [B] therapeutic areas (namely oncological disorders, genetic disorders, metabolic disorders and others) [C] routes of administration (intravenous and others) and [D] geography (North America, Europe, Asia Pacific and the rest of the world) .
Section V Analysis of Returns on Investment & Key Acquisition Targets
Chapter 15 includes case studies of instances where investors have exited various cell and gene therapy-related ventures, offering insights on returns on investment made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time.
Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.
Chapter 17 provides a pictorial summary of the overall project.
Chapter 18 is a set of appendices.
Table of Contents
Excel Deliverable1. Key Innovators & Products Dataset
1.1. Analysis Notes
1.2. Summary Dashboard
1.3. Innovators Landscape Dataset
1.4. Product Landscape Dataset
1.5. Company Health Indexing
1.6. Value Proposition Analysis
1.7. Key Acquisition Targets
A1 - A8 Appendices
2. Funding & Investments Analysis
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in cell and gene therapy
A1 - A2 Appendices
3. Company Valuation Analysis
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
A1 - A2 Appendices
4. Fundamental & Technical Financial Analysis
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends.
5. Business Risk Analysis
5.1. Analysis Notes
5.2. Business Risk Data
A1 - A2 Appendices
6. Market Forecast & Opportunity Analysis
6.1. Analysis Notes
6.2. Summary Dashboard
6.3. Market Forecast & Opportunity Analysis
A1 - A2 Appendices
7. Returns on Investment
7.1. Analysis Notes
7.2. Estimated RoI for Investors in Company A
7.3. Estimated RoI for Investors in Company B
7.4. Estimated RoI for Investors in Company C
7.5. Estimated RoI for Investors in Company D
7.6. Estimated RoI for Investors in Company E
7.7. Estimated RoI for Investors in Company F
7.8. Estimated RoI for Investors in Company G
7.9. Estimated RoI for Investors in Company H
7.10. Estimated RoI for Investors in Company I
7.11. Estimated RoI for Investors in Company J
A1 - A2 Appendices
PowerPoint Deliverable
1. Context
2. Project Approach
3. Project Objectives
4. Executive Summary
Section I: Need for Cell and Gene Therapy & Key Innovators Landscape
5. The Cell and Gene Therapy Market
5.1. Overview
5.2. Contemporary Sentiments & Expert Opinions
5.3. Key Areas of Application
5.4. Benefits of Cell and Gene Therapies
5.5 Developmental History
5.6 Exemplary Products
5.7. Challenges related to Cell and Gene Therapies
5.7 Key Initiatives in the Cell and Gene Therapy Market (Case Studies)
5.8.1. Exemplary Business Successes
5.8.2. Exemplary Business Failures
5.9. Analysis of Recent Conferences
6. Key Innovators Competitive Landscape
6.1. Key Innovators in the Cell and Gene Therapy Market
6.2. Analysis of Developer Landscape
7. Products Landscape & Company Health Indexing
7.1. List of Products
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
7.3. Concluding Remarks
8. Value Proposition Analysis
8.1. Overview & Methodology
8.2. Therapy Related Value
8.3. Value to Patients
8.4. Technology Related Value
8.5. Developer Value
9. Company Competitiveness Analysis
9.1. Overview & Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks
Section II Analysis of Investments & Company Valuation
10. Funding and Investments Analysis
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography
10.4. Most Active Companies and Popular Investors
10.5. Analysis of Trends Associated with Individual Funding Categories
10.6. Funding and Investments Summary
11. Company Valuation Analysis
11.1. Overview & Methodology
11.2. Results of Valuation Analysis
Section III Financial Analysis & Assessment of Business Risks
12. Financial Analysis of Public Ventures
12.1. Overview
12.2. Company A
12.2.1. Fundamental Analysis of Company Financials
12.2.1.1. Insights from Balance Sheet
12.2.1.2. Analysis of Financial Ratios
12.2.2. Technical Analysis of Stock Price
12.2.2.1. Historical Trends
12.2.2.1. Recent Trends
12.3. Company B
12.3.1. Fundamental Analysis of Company Financials
12.3.1.1. Insights from Balance Sheet
12.3.1.2. Analysis of Financial Ratios
12.3.2. Technical Analysis of Stock Price
12.3.2.1. Historical Trends
12.3.2.1. Recent Trends
12.4. Company C
12.4.1. Fundamental Analysis of Company Financials
12.4.1.1. Insights from Balance Sheet
12.4.1.2 Analysis of Financial Ratios
12.4.2. Technical Analysis of Stock Price
12.4.2.1. Historical Trends
12.4.2.1. Recent Trends
12.5. Company D
12.5.1. Fundamental Analysis of Company Financials
12.5.1.1. Insights from Balance Sheet
12.5.1.2. Analysis of Financial Ratios
12.5.2. Technical Analysis of Stock Price
12.5.2.1. Historical Trends
12.5.2.1. Recent Trends
12.6. Company E
12.6.1. Fundamental Analysis of Company Financials
12.6.1.1. Insights from Balance Sheet
12.6.1.2 Analysis of Financial Ratios
12.6.2. Technical Analysis of Stock Price
12.6.2.1. Historical Trends
12.6.2.1. Recent Trends
12.7. Company F
12.7.1. Fundamental Analysis of Company Financials
12.7.1.1. Insights from Balance Sheet
12.7.1.2 Analysis of Financial Ratios
12.7.2. Technical Analysis of Stock Price
12.7.2.1. Historical Trends
12.7.2.1. Recent Trends
12.8. Company G
12.8.1. Fundamental Analysis of Company Financials
12.8.1.1. Insights from Balance Sheet
12.8.1.2 Analysis of Financial Ratios
12.8.2. Technical Analysis of Stock Price
12.8.2.1. Historical Trends
12.8.2.1. Recent Trends
12.9. Company H
12.9.1. Fundamental Analysis of Company Financials
12.9.1.1. Insights from Balance Sheet
12.9.1.2 Analysis of Financial Ratios
12.9.2. Technical Analysis of Stock Price
12.9.2.1. Historical Trends
12.9.2.1. Recent Trends
12.10. Company I
12.10.1. Fundamental Analysis of Company Financials
12.10.1.1. Insights from Balance Sheet
12.10.1.2 Analysis of Financial Ratios
12.10.2. Technical Analysis of Stock Price
12.10.2.1. Historical Trends
12.10.2.1. Recent Trends
12.11. Company J
12.11.1. Fundamental Analysis of Company Financials
12.11.1.1. Insights from Balance Sheet
12.11.1.2 Analysis of Financial Ratios
12.11.2. Technical Analysis of Stock Price
12.11.2.1. Historical Trends
12.11.2.1. Recent Trends
13. Business Risk Analysis
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.8. Business Risk Summary
Section IV Market Forecast & Opportunity Analysis
14. Market Forecast and Opportunity Analysis
14.1. Overview and Methodology
14.2. Overall Cell and Gene Therapy Market Size, 2021-2035
14.2.1. Analysis by Key Market Segments
14.2.2. Analysis by Geography
14.2.3. Concluding Remarks
Section V Analysis of Returns on Investment & Key Acquisition Targets
15. Analysis of Returns on Investment
15.1. Overview & Methodology
15.2. Case Studies
15.3. Concluding Remarks
16. Key Acquisition Targets
16.1. Overview
16.2. List of Key Acquisition Targets
16.3. Concluding Remarks
17. Conclusion
18. Appendices
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4BIO Capital
- 4D Molecular Therapeutics
- 5AM Venture
- 600 Mile Challenge Fund
- AavantiBio
- aaVective
- AAVogen
- Abata Therapeutics
- AbbVie Ventures
- Abby Grace Foundation
- AbCheck
- AbClon
- Abdi Ibrahim
- Abeona Therapeutics
- Abingworth
- Abintus Bio
- Access Biotechnology
- Adage Capital Management
- Adaptate Biotherapeutics
- Adaptimmune Therapeutics
- Adicet Bio
- Adjuvant Capital
- Advantagene
- Advaxis
- Adverum Biotechnologies
- Aegle Therapeutics
- Aeon Therapeutics
- Affinia Therapeutics
- AffyImmune Therapeutics
- Agent Capital
- AgenTus Therapeutics
- Agenus
- AGTC
- AIG
- Aisling
- Aisling Capital
- AJU IB Investment
- Akouos
- Alexandria Venture Investments
- Algot Invest
- Aligned Genetics
- Allergan
- ALLIFE
- Allogene Therapeutics
- AlloVir
- Ally Bridge Group
- Alpha Holdings
- AlphaVax
- Altaco XXI
- Altheia Science
- Altitude Life Science Ventures
- Altor Bioscience
- Alumni Ventures
- Amarna Therapeutics
- Ambulero
- American Gene Technologies
- Amgen
- Amgen Ventures
- Amicus Therapeutics
- Amplo
- Anaeropharma Science
- AnGes
- Angiocrine Bioscience
- Angionetics
- Anhui Kedgene Biotechnology
- Antagene
- Anterogen
- Anzu Partners
- apceth Biopharma
- ApolloBio
- Apple Tree Partners
- ARBELE
- Arcane Investment
- Arcellx
- Arch Overage Fund
- ARCH Venture Partners
- Arctic Light Venture Capital
- Arix Bioscience
- Arkin Bio Ventures
- ArrowMark Partners
- ARTIS Ventures
- Aruvant Sciences
- ASC Therapeutics
- Ascendant BioCapital
- Asia Alpha
- Asklepios BioPharmaceutical (AskBio)
- Aspire Capital Fund
- Astellas Pharma
- Astellas Venture Management
- AstraZeneca
- Atara Biotherapeutics
- Athersys
- Atlas Venture
- Atsena Therapeutics
- Audentes Therapeutics
- Auriga Partners
- Aurora Biopharma
- Autolus
- Avacta
- AveXis
- Avidity Partners
- AVROBIO
- Axis Biotec Brasil
- Axovant Gene Therapies
- Azidus Brasil
- Baillie Gifford
- Bain Capital Life Sciences
- Barer & Son Capital
- Bayer Global Investments
- Baylx
- BB Pureos Bioventures
- Beam Therapeutics
- Beijing 302 Hospital
- Beijing Biohealthcare Biotechnology
- Beijing Doing Biomedical
- Beijing Immunochina Medical Science & Technology
- Bellicum Pharmaceuticals
- Berkeley Catalyst Fund
- BHI Therapeutic Sciences
- BHT Lifescience Australia
- BioAtla
- BioCardia
- Bioceltech Therapeutics
- Biogen
- BioGenCell
- Bioinova
- BioInvent International
- BioMarin Pharmaceutical
- Biomatics
- Biomatics Capital
- Bionic Sight
- BioNTech
- Bioquark
- BioRestorative Therapies
- BioTrack Capital
- BioVec Pharma
- Bioverativ
- Biox Biosciences
- Birk Venture
- BlackRock
- Blackstone Life Sciences
- Blue Bear Ventures
- Blue Water Angels
- bluebird bio
- Bluebird Ventures
- BlueWater Angels
- Boehringer Ingelheim
- Boehringer Ingelheim Venture Fund
- Bone Therapeutics
- Boxer Capital
- Boxer Capital of Tavistock Life Sciences
- BPI France
- Bpifrance
- Brace Pharma Capital
- Brahman Investment
- Brain Neurotherapy Bio
- BrainStorm Cell Therapeutics
- BrainVectis
- Breakout Ventures
- BridgeBio
- BrightGene
- Bristol-Myers Squibb
- Brookside Capital
- Bukwang Pharmaceutical
- BVF Partners
- C4 holding
- CaaS Capital
- Caladrius Biosciences
- CAM Capital
- Cambridge Enterprise
- Cambridge Gene Therapy
- Cambridge Innovation Capital
- Camford Capital
- CapDecisif Management
- Capricor Therapeutics
- CARB-X
- Carina Biotech
- Carmine Therapeutics
- CARsgen Therapeutics
- CAR-T (Shanghai) Biotechnology
- CAR-T (Shanghai) Cell Biotechnology
- Cartesian Therapeutics
- Cartherics
- Casdin Capital
- Castle Creek Biosciences
- Catalyst Biosciences
- CavoGene LifeSciences
- Celgene Corporation
- Celixir
- Cell Therapy Catapult
- Cellectis
- Cellenkos
- Cellerant Therapeutics
- CellGenTech
- CellProthera
- Cellular Biomedicine Group
- Cellular Therapeutics
- Celsion
- Celyad Oncology
- CENTOGENE
- Cesca Therapeutics
- CG Oncology
- CHABiotch
- Chiesi Farmaceutici
- Chiesi Ventures
- China Immunotech (Beijing) Biotechnology
- China Merchant Bank International Capital
- Chiyoda-ku
- Chongqing Precision Biotech
- Chongqing Precision Biotechnology
- Clarus Ventures
- Clough Capital Partners
- CMG-SDIC Capital
- CODA Biotherapeutics
- Codexis
- Columbus Venture Partners
- CombiGene
- Consort Medical
- Copernicus Therapeutics
- Corestem
- Cormorant Asset Management
- Cormorant Capital
- Cota Capital
- Cowen Group
- Co-Win Ventures
- Coya Therapeutics
- CRISPR Therapeutics
- CSL Behring
- CureDuchenne Ventures
- Cynata Therapeutics
- Cynvec
- Cystic Fibrosis Foundation Therapeutics
- CytoMed Therapeutics
- Cytopeutics
- Cytovant Sciences
- D1 Capital Partners
- DA Value Partners
- DAG Ventures
- Daily Partners
- Deerfield Management Company
- DEFTA Partners
- Dexcel Pharma
- DiNAQOR
- DiscGenics
- DNAlite Therapeutics
- DNAtrix
- Domain Associates
- Driehaus Capital Management
- DriveCapital
- DS Asset Management
- Dyno Therapeutics
- EB Medical Research Foundation
- EB Research Partnership
- EB5 Life Sciences
- EcoR1 Capital
- Editas Medicine
- EHL Bio
- Eight Roads Ventures
- Elaia Partners
- Elevate Bio
- Eli Lilly
- Emendo Biotherapeutics
- Encoded Therapeutics
- Endocyte
- Endsulin
- Enochian BioSciences
- Entos Pharmaceuticals
- Epeius Biotechnologies
- EpiBone
- EpiVax
- EPS Holdings
- Errant Gene Therapeutics
- Esco Ventures
- Essex Bio-Technology
- Esteve
- Eureka Therapeutics
- eureKARE
- Eurofancolen
- Eutilex
- Eventide Asset Management
- Ever Supreme Bio Technology
- Evotec
- Excision BioTherapeutics
- Exegenesis Bio
- Expression Therapeutics
- ExSight Capital
- EXUMA Biotech
- Eyevensys
- F2 Ventures
- Farallon Capital
- Fate Therapeutics
- FerGene
- Ferrer International
- Ferring Pharmaceuticals
- FF Science
- Fibrocell Science
- Fidelity Biosciences
- Fidelity Management & Research Company
- Fin Posillipo
- Five Prime Therapeutics
- Flagship Pioneering
- Flagship Ventures
- Flanders Innovation & Entrepreneurship
- Flash Therapeutics
- Flerie Invest
- Flexion Therapeutics
- Forbion’s Growth Opportunities Fund
- Foresite Capital Management
- Forevertek Biotechnology
- Forge Biologics
- Formula Pharmaceuticals
- Fortress Biotech
- Fosun Capital
- Fosun Pharma
- Fountain Healthcare Partners
- FoxKiser and Fidelity BioSciences
- F-Prime Capital
- Franklin Templeton Investments
- Frazier Healthcare Partners
- Freeline Therapeutics
- Friedreich’s Ataxia Research Alliance
- FS Development
- Fujian Cancer Hospital
- Fund+
- Fundamenta Therapeutics
- Gadeta
- Galia Gestion
- Gamida Cell
- GammaCell Bio-Technologies
- GammaDelta Therapeutics
- GC Cell
- Gemini Therapeutics
- Gene Therapy Research Institution
- GeneCure Biotechnologies
- Genelux
- GeneMedicine
- Genenta Science
- GeneOne Life Science
- GeneQuine Biotherapeutics
- Generation Bio
- Genespire
- Genethon
- Genexine
- Genocea
- Genprex
- GenSight Biologics
- GentiBio
- Genus Oncology
- GenVec
- Genzyme
- Georgia Research Alliance
- Ghost Tree Capital Group
- GigaGen
- Gilde Healthcare
- Gilead Sciences
- GlaxoSmithKline
- Global Cell Med
- Glycostem Therapeutics
- GN Tech Venture
- GO CAPITAL
- GOFAR
- Google Venture
- Gracell Biotechnologies
- Gradalis
- Grand Mount Capital
- Gray’s Creek Capital Partners
- GreatPoint Ventures
- Green Cross Holdings
- Guangzhou FineImmune Biotechnology
- Guangzhou Institute of Respiratory Disease
- Guofang Capital
- Gwo xi Stem Cell
- Gyroscope Therapeutics
- Handl Therapeutics
- Harvest Capital
- Hatteras Venture Partners
- HBM Healthcare Investments
- HealthCap
- Hebei Newtherapy BIo-Pharma Technology
- Hebei Senlang Biotechnology
- Helix BioPharma
- Helixmith
- Hemera Biosciences
- Hemostemix
- Henan Hualong Biotechnology
- Herantis Pharma
- Hercules Capital
- Hercules Technology Growth Capital
- High-Tech Gründerfonds
- Hillhouse Capital Group
- Hiroshima Venture Capital
- Hitachi Chemical
- Hoga
- Holostem Terapie Avanzate
- Homology Medicines
- Hongkou
- Hope Biosciences
- HORAMA
- Horizon Discovery
- Horizon Technology Finance Corporation
- Hovione Scientia
- Hrain Biotechnology
- HuaDao (Shanghai) Biomedical
- Huapont Life Sciences
- iCarTAB BioMed
- iCell Gene Therapeutics
- Icell Kealex Therapeutics
- Idinvest
- Ikarian Capital
- Ikarovec
- Illumina Ventures
- Ilya Pharma
- Immatics
- Immetacyte
- Immune Therapeutics
- Immunocore
- Immusoft
- Imperial Innovations
- Imperial Innovations Group
- IN8bio
- Inception Capital Management
- Index Ventures
- IndusAge Partners
- InnoAngel
- Innobio
- Innovate UK
- Innovative Cellular Therapeutics
- InnoVision Capital
- Inovio Pharmaceuticals
- Inserm Transfert
- Intellia Therapeutics
- Intima Bioscience
- Invectys
- Invesco Perpetual
- Investment bank of the state of Brandenburg
- Invus
- Iovance Biotherapeutics
- PolyBioCept
- IVERIC bio
- Janssen
- Janus Capital Management
- Japan Tissue Engineering
- jCyte
- JDRF T1D Fund
- Jennison Associates
- JINWEI
- Johnson & Johnson Development
- JSC Lancaster Group
- Juda Capital
- JumpStart
- Juno Therapeutics
- Juventas Cell Therapy
- JW Biotechnology
- JW Therapeutics
- K2 Venture Partners
- Kadimastem
- KAEDI
- Kangstem Biotech
- Kecellitics Biotech
- Key Biologics
- Kissei Pharmaceutical
- Kite Pharma
- KKR
- Kleiner Perkins Caufield & Byers
- KLSMC Stem Cells
- Kodikaz Therapeutic Solutions
- Kolon Investment
- Kolon TissueGene
- Korea Investment Partners
- Kriya Therapeutics
- Krystal Biotech
- KSQ Therapeutics
- K-Stem Cell
- Kubota Vision
- Kurma Partners
- Kuur Therapeutics
- Kyorin Pharmaceutical
- Kyverna Therapeutics
- Lacerta Therapeutics
- Lai Corporation
- Lake Bleu Capital
- Laurion Capital Management
- Lava Therapeutics
- Leerink Partners
- Leeyeon Investment Association
- Leeyon Pharmaceutical
- Legend Biotech
- Legend Capital
- Lentistem® Biotech
- Leucid Bio
- LEXEO Therapeutics
- Life Sciences Partners
- LifeArc
- Lightstone Ventures
- Lilly Asia Ventures
- Limelight Bio
- Liminatus Pharma
- Lineage Cell Therapeutics
- Linked Vision
- Lion TCR
- Living Pharma
- LogicBio Therapeutics
- Logos Capital
- Lokon Pharma
- Longeveron
- Longitude Capital
- Longwood Fund
- Loreda Holdings
- Lumira Ventures
- Lundbeckfond Ventures
- Lupus Ventures
- LYFE Capital
- Lysogene
- Lytix Biopharma
- MabVax Therapeutics Holdings
- Magellan Biologicals
- Magenta Therapeutics
- Malin Corporation
- Mangrove Partners
- Marshall Wace
- Matrix Capital Management
- Maverick Ventures
- MaxCyte
- Med Cell Bahamas
- Medeor Therapeutics
- Medigene
- MEDIPOST
- Medisix Therapeutics
- Medison Ventures
- MeiraGTx
- Melbourne Stem Cell Centre
- Mercia Technologies
- Merck
- Meridigen Biotech
- Mesa Verde Venture Partners
- Mesoblast
- Michigan Economic Development
- MidCap Financial
- Midven’s Rainbow Seed Fund
- Mie University
- Milo Biotechnology
- Miltenyi Biomedicine
- Miltenyi Biotec
- Minerva Biotechnologies
- MingJu Therapeutics
- Minovia Therapeutics
- MiraeAsset Financial Group
- Mitsubishi Tanabe Pharma
- MolMed
- Momotaro-Gene
- Morningside
- MPM Capital
- MRL Ventures Fund
- MultiVir
- Muscular Dystrophy Association
- Mustang Bio
- Myosana Therapeutics
- Nanjing Bioheng Biotech
- NanoCor Therapeutics
- Narya Capital
- National Holdings
- Nature Cell
- Navega Therapeutics
- Nektar Therapeutics
- NeoMed
- Nerveda
- Netherlands Enterprise Agency
- NeuExcell Therapeutics
- Neuracle Genetics
- Neurogene
- NeuroGeneration
- Neurophth Therapeutics
- New Enterprise Associates
- New Leaf Venture Partners
- NexImmune
- NextCell Pharma
- Ninevah Therapeutics
- Nippon Regenerative Medicine
- Nipro
- Nissei Capital No. 9
- Nitosei Capital
- Noga Therapeutics
- Nohla Therapeutics
- Noile-Immune Biotech
- Nolan Capital
- Noray Biosciences Group
- Northern Light Venture Capital
- Northpond Ventures
- Norwegian Research Council
- Norwest Venture Partners
- Noshaq
- Nova Immunotherapeutics
- Novadip Biosciences
- Novartis
- Novartis Pharmaceuticals
- Novartis Venture Fund
- Novo Holdings
- Novo Nordisk
- Novo Ventures
- NuVasive
- Oaktree Capital Management
- Obsidian Therapeutics
- Octagon Capital
- Ocugen
- Odylia Therapeutics
- Olive Tree Capital
- Omega Funds
- Omnes Capital
- Omnimed Capital
- Oncolys BioPharma
- Onconetics Pharmaceuticals
- OncoSec Immunotherapies
- oNKo-innate
- Ono Pharmaceutical
- Optipharm
- OrbiMed
- Orca Bio
- ORCA Therapeutics
- Orchard Therapeutics
- ORI Capital
- ORI Healthcare Fund
- Oriza Holdings
- Orphinic Scientific
- Orthofix
- OS Therapies
- Osage University Partners
- Osiris Therapeutics
- Otonomy
- ovio Pharmaceuticals
- Oxford BioMedica
- Oxford Finance
- Oxular
- Pacira BioSciences
- PACT Pharma
- Pappas Capital
- Paragon Biosciences
- Parent Project Muscular Dystrophy
- Parkwalk
- Partners Innovation Fund
- Partners Investment
- Passage Bio
- Patient Square Capital
- Pattern BioScience
- Pavilion Capital
- PBM Capital
- PeproMene Bio
- Perceptive Advisors
- Perceptive Xontogeny Venture Fund
- PeriphaGen
- Perseverance Capital Management
- Personalized Stem Cells
- PersonGen BioTherapeutics (Suzhou)
- Pfizer
- Pfizer Venture Investments
- Pfizer Ventures
- Pharmicell
- Phio Pharmaceuticals
- Phoenix Nest
- PhorMed
- Piedmont Capital Partners
- Pinze Lifetechnology
- Pivotal bioVenture Partners
- Pluristem Therapeutics
- Plus Therapeutics
- Polaris Partners
- PolyBioCept
- Pontifax Venture Capital
- POSCO Capital
- Poseida Therapeutics
- Precigen
- Precision BioSciences
- Prevail Therapeutics
- Progenics Pharmaceuticals
- ProMab Biotechnologies
- Promethera Biosciences
- Protheragen
- PsiOxus Therapeutics
- PTC Therapeutics
- Q Therapeutics
- Quad Asset Management
- Quell Therapeutics
- QVT
- RA Capital Management
- RBV Capital
- Redbiotec
- Redmile Group
- Redpin Therapeutics
- Regeneron Pharmaceuticals
- Regeneus
- Regenexx
- REGENXBIO
- Reliance Life Sciences
- ReNeuron
- Renova Therapeutics
- resTORbio
- Rev1 Ventures
- Reyon Pharmaceutical
- Ridgeback Capital Management
- Ring Therapeutics
- Riordan Technologies
- RO Invest
- Roche
- Roche Venture Fund
- Rock Springs Capital Management
- Rocket Pharmaceuticals
- ROHTO Pharmaceutical
- Rottapharm Biotech group
- RTI Surgical
- RTW Investments
- RVO
- Sabby Capital
- Saehan Startup Investment
- Salvat
- Samsara BioCapital
- Samum Vermögensverwaltungs
- SanBio
- Sanford Health
- Sangamo Therapeutics
- Sanofi
- Sanofi Ventures
- Santen Pharmaceutical
- Sarepta Therapeutics
- SBI Japan-Israel Innovation Fund
- Scancell
- Sclnow Biotechnology
- SCM Lifescience
- Scotia Biologics
- SDL Ventures
- Seattle Genetics
- Selecta Biosciences
- Seneca Biopharma
- Sensei Biotherapeutics
- Sentien Biotechnologies
- Sequoia Capital China
- Seroba Life Sciences
- Servier
- Seven Tree Equity Partners
- Sham Innovation Santé
- Shandong Qilu Stem Cells Engineering
- Shanghai Biomed-Union Biotechnology
- Shanghai Bioray Laboratory
- Shanghai GeneChem
- Shanghai iCELL Biotechnology
- Shanghai Longyao Biotechnology
- Shanghai PerHum Therapeutics
- Shanghai Sunway Biotech
- Shanghai Unicar-Therapy Bio-medicine Technology
- Shenzhen Binde Biotechnology
- Shenzhen BinDeBio
- Shenzhen Hornetcorn Biotechnology
- Shenzhen Qianhai Taxus
- Shire
- Sibiono GeneTech
- SIGHT AGAIN project
- Silicon Valley Bank
- SillaJen
- Sinobioway Cell Therapy
- Skolkovo Foundation
- SMBC venture
- SNU Bio Angel
- Sofinnova Ventures
- Sofinnova Investments
- Solid Biosciences
- Song Hong Fang
- Sonoma Biotherapeutics
- Sorrento Therapeutics
- SOSV
- Spark Therapeutics
- Sphera Global Healthcare
- Spirovant Sciences
- SpringWorks Therapeutics
- SROne
- Stem Cell Medicine
- Stem Med
- Stemedica Cell Technologies
- Steminent Biotherapeutics
- Stempeutics Research
- StrideBio
- Stryker
- Sumitomo Dainippon Pharma
- Sun Pharmaceutical Industries
- Sunshine Insurance
- Surveyor Capital
- Suvretta Capital Management
- SV Health Investors
- SV Investment
- SV Life Sciences
- SVE Capital
- SwanBio Therapeutics
- Swiss Medica XXI Century
- Syncona
- SYZ Cell Therapy
- T. Rowe Price Associates
- Tactiva Therapeutics
- Taiwan Bio Therapeutics
- Takara Bio
- Takeda
- Takeda Pharmaceutical
- Takeda Pharmaceuticals
- Takeda Ventures
- Talaris Therapeutics
- Targazyme
- Target ALS Foundation
- Targovax
- Tasly Biopharmaceuticals
- Taysha Gene Therapies
- TC BioPharm
- TCG
- TCR CURE Biopharma Technology
- TCR2 Therapeutics
- T-Cure Bioscience
- Tech Coast Angels
- Techlife Capital
- Technium Partners
- Temasek
- Tenaya Therapeutics
- TeneoBio
- TeraImmune
- Terumo
- Tessa Therapeutics
- Tetragon Financial Group
- Tevogen Bio
- The Abby Grace Foundation
- The Baldota family
- The Baupost Group
- The Biotechnology Value Fund
- The Board of Trustees of the Leland Stanford Junior University
- The Column Group
- The Emmes Company
- The Pregene (ShenZhen) Biotechnology
- Théa Open Innovation
- TheraBiologics
- Theravectys
- Third Rock Ventures
- Tianhe Stem Cell Biotechnologies
- Tianjin Ever Union Biotechnology
- Tianjin Mycure Medical Technology
- Tianjin Weikai Biological Engineering
- TICEBA
- TILT Biotherapeutics
- Timmune Biotech
- Tmunity Therapeutics
- Tolerion
- ToolGen
- TPG Biotech
- TRACT Therapeutics
- Transgene
- Transhuman Capital
- Triumvira Immunologics
- Trucode Gene Repair
- Trygve Schiørbeck
- Tscan Therapeutics
- Tsingyuan
- U.S. Stem Cell
- UCB Ventures
- UCL Technology Fund
- UF Innovate Ventures
- UK start-up investors UKI2S
- Ulmer Investment
- Ultragenyx
- uniQure Biopharma
- United Therapeutics
- University of California Berkeley
- Unum Therapeutics
- UPMC Enterprises
- Urovant Sciences
- UWELL Biopharma
- Valor Equity Partners
- V-Bio Ventures
- VBL Therapeutics
- VcanBio Center for Translational Biotechnology
- VCN Biosciences
- Venrock
- Vericel
- Verition Fund Management
- Versant Ventures
- Vertex Pharmaceuticals
- Verve Therapeutics
- ViaCyte
- Vida Ventures
- ViGenCell
- ViGeneron
- Viking Global Investors
- Vir Biotechnology
- ViroMed
- Viscofan BioEngineering
- Vivet Therapeutics
- Vivo Capital
- Voyager Therapeutics
- VREX Therapeutics
- VT BIO
- Waverly Capital
- Wellcome Trust
- Wellington Management Company
- Wellington Zhaotai Therapies
- Whitesun Healthcare Ventures
- WI Harper Group
- WindMIL Therapeutics
- Wize Pharma
- Woodford Investment Management
- Woodline Partners
- WRVI Capital
- Wugen
- Wuhan Bio-Raid Biotechnology
- Wuhan Sian Medical Technology
- WuXi AppTec and Sequoia Capital China
- Wyvern Pharmaceuticals
- Xi'An Yufan Biotechnology
- Xiangxue Life Sciences
- XyloCor Therapeutics
- Youkyung PSG Asset Management
- Ysios Capital
- YuanBio
- Yuanyi Biotechnology
- Zelluna Immunotherapy
- Zhujiang Hospital
- Ziopharm Oncology
Methodology
LOADING...
